Navigation Links
SaltCheck Develops First Simplified Test for Monitoring Salt Intake in People With Hypertension
Date:2/26/2009

BOSTON, Feb. 26 /PRNewswire/ -- SaltCheck, Inc. announced the completion of a 100 subject study demonstrating successful use of a new simplified test for monitoring sodium intake. The test, which can be used either for self-monitoring by people with hypertension, or for point-of-care testing at the physician's office, is revolutionary in providing immediate feedback on urine sodium excretion, which closely mirrors sodium intake. It involves dipstick testing, with results refined by statistical adjustments derived from a series of clinical studies.

The World Health Organization estimates there are over 600 million people globally with hypertension, and salt intake is known to affect blood pressure and/or response to blood pressure medication in most. Awareness of salt intake, and efforts to reduce salt intake are receiving increasing emphasis. The National Institutes of Health has recommended limiting intake of salt upon diagnosis of hypertension.

The studies, which were conducted at Weill Cornell Medical College, and sponsored by SaltCheck, Inc., accurately estimated sodium excretion from a simple spot check of urine. The SaltCheck test provides a snapshot of the state of sodium excretion, and also correctly indicates whether a patient's sodium excretion over a 24-hour period is low or not, with a high degree of sensitivity and specificity. Most important, it will be the first commercially-available test for assessing salt intake, and its ease of use and low cost will readily enable serial monitoring of salt intake, and of the effect of efforts to change salt intake.

The test also eliminates the two biggest drawbacks of the current testing method, which consists of collecting all urine during a 24 hour period, and sending it to a laboratory. "The standard test is frequently inaccurate because of incomplete collections, reflecting the difficulty and impracticality of collecting all urine for 24 hours. Worse, because the test is so cumbersome, very few doctors and patients ever evaluate salt intake, despite the growing and widespread awareness of its importance in managing hypertension," commented Marc Eichenberger, COO of Allied Minds, the parent company of SaltCheck.

Owing to its ease of use, suitability for serial monitoring, and accuracy of results, SaltCheck has the potential to help in the management of many millions with hypertension. Surveys suggest that physicians would embrace testing of their patients' salt intake if a convenient and inexpensive test were available. Testing could also help improve patient compliance with drug and dietary prescriptions.

"We are extremely pleased with the results from this significant study and the commercial progress to-date of the company. We very much look forward to bringing this groundbreaking test to the market to help patients and doctors worldwide in managing hypertension," added Mr. Eichenberger.

About SaltCheck, Inc. and Allied Minds, Inc.

SaltCheck is a privately-held startup company formed by Allied Minds, Inc. to commercialize a groundbreaking patient salt intake monitoring system that doesn't require laboratory facilities. The technology was originally developed at Weill Cornell Medical College by Drs. Samuel Mann and Linda Gerber, who conducted the studies reported here. For more information, please visit the SaltCheck website: www.saltcheck.com.

Allied Minds, Inc. is the premier seed organization for early-stage technology. The company focuses on converting academic discoveries into commercial reality by working exclusively with a network of U.S. universities and national labs. By filling the gap between government grants and traditional venture capitalists, Allied Minds focuses on funding innovations with significant transformative potential. Instead of managing funds, the company fosters early-stage companies through to success, generating value for all stakeholders. Allied Minds has a nationwide footprint with offices in Boston, Seattle, Washington, D.C. and Los Angeles, and a European presence in London, United Kingdom. Website: www.alliedminds.com

Disclosure

Weill Cornell Medical College requires their faculty members Drs Mann and Gerber to disclose that they and Weill Cornell Medical College have a potential financial interest in the outcome of this study.


'/>"/>
SOURCE SaltCheck, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Couples more likely to divorce if spouse develops cervical or testicular cancer
2. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
3. UCLA doctor develops new technique to treat varicose veins
4. Biomarkers predict risk for invasive breast cancer years before the tumor develops
5. Silverchair Learning Systems Updates and Develops New Courses
6. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
7. Capsulated Systems, Inc. Develops Long Term Local Anesthetic
8. MIT develops thin-film micro pharmacy
9. Omron Healthcare Develops Solar-Powered Digital Blood Pressure Monitors
10. Psychologist develops post-operative care for heart patients in Bermuda
11. Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... College District , the only authorized OSHA Training Institute Education Center headquartered in ... by protecting their workers from extreme heat at their worksites. Employers with ...
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: